BRIDGETOWER-CAPITAL
23.3.2022 17:05:05 CET | Business Wire | Press release
BridgeTower Capital, an innovator in connecting blockchain markets globally, is partnering with Securitize, the leader in digital assets securities, to launch the BridgeTower Global Platform offering for Permissioned Markets. BridgeTower is also launching a Staked Digital Asset Security (SDAS) that will run in an Avalanche subnet .
BridgeTower is partnering with Securitize, its digital transfer agent, to offer its products through a seamless user interface. Investors simply need to create a Securitize iD, in which their identity is verified consistent with U.S. regulatory standards. They can then invest easily in opportunities across the BridgeTower ecosystem, as well as Securitize’s own offerings, including shares in private companies and institutional grade funds.
Transactions will utilize smart contracts and regulated custodians will provide transparency around asset collateralization using Chainlink Proof of Reserve, the market-leading oracle solution for auditing on-chain and off-chain reserves. Using Chainlink Proof of Reserve to verify the collateral of wrapped tokens across the multi-chain ecosystem, BridgeTower’s Permissioned Markets will unlock asset liquidity across many of the world’s most significant blockchains.
BridgeTower’s Permissioned markets will include DeFi financial products such as customized blockchain staking opportunities, token swaps and NFT development with arts, entertainment, and sporting ventures to provide seamless, institutionally compliant products.
With more than 5,000 of its own Staking Nodes, BridgeTower utilizes renewable energy to reduce the carbon footprint. Already a leading proof-of-stake infrastructure provider for leading Layer 1 blockchains and Web 3.0 companies, BridgeTower has built its fast-growing foundational staking and DeFi business through partnerships and investments over the past few years.
“We are bridging the value of innovative blockchain staking and DeFi products seamlessly to institutional investors,” said BridgeTower CEO Cory Pugh. “We have worked tirelessly to bring innovation and regulated processes by using our staking and DeFi products in Permissioned Markets to create a compliant gateway for institutions to participate in the evolving blockchain opportunity.”
“There is significant institutional demand to participate in DeFi opportunities, but the lack of safe places to participate has kept institutions on the sidelines. Now that Securitize is offering permissioned DeFi through on-chain attestations, as well as through our partnership with Avalanche to build a permissioned subnet, the doors to regulated DeFi have opened,” said Jamie Finn, president, and co-founder of Securitize. “The globally integrated platform BridgeTower has created will enable more institutions to enter the market confidently.”
AVAX STAKED DIGITAL ASSET SECURITY TO LAUNCH
"Avalanche has rapidly become the preferred destination for institutions to access the innovation emerging from decentralized finance and contribute their own expertise in creating products and ecosystems of value on-chain. I'm excited to see BridgeTower and Securitize expanding their involvement in the Avalanche community and building institutional-grade applications," said John Nahas, VP of Business Development at Ava Labs.
BridgeTower’s most recent product innovation is a Staked Digital Asset Security. The new security will receive staking rewards, and after one year’s hold time can be traded in the Permissioned Market. The AVAX Staking Security token will represent staked AVAX utilizing Smart Contracts, to mint staked utility tokens on the Avalanche Chain and run across a subnet. This will create a single digital asset security designed for institutional investors capable of administering KYC, whitelisting, cap table management and reporting. BridgeTower will launch additional products later this year.
The Digital Staking Asset AVAX Security will also be offered on the Securitized Markets Alternative Trading System making it available to a wide range of accredited investors. Currently, there are more than 400,000 investors participating in Securitize Markets. Eventually, it is expected that the AVAX Staked Digital Asset Security, and other Institutional-grade staking securities will also be offered on Layer 1, Web 3.0, and eventually other exchanges.
“We believe this product is unique, as a security, and will be attractive to institutional investors who are looking for a regulated, global security to participate in the dramatically expanding blockchain proof-of-stake market,” Pugh added. “We are thrilled to partner with Securitize and Avalanche and for the expertise they bring as industry leaders in their respective areas.”
About BridgeTower
BridgeTower Capital has developed a global platform to uniquely bring products to its own permissioned markets to seamlessly enable an institutional gateway to staking, DeFi, NFT and Web 3.0 entities. BridgeTower operates more than 5,000 of its own staking nodes and owns servers utilizing 100 percent renewable energy. Significant portions of returns from these products are reinvested to continually grow BridgeTower’s infrastructure and assets. BridgeTower is a global company based in Singapore with operating entities in Switzerland and the United States allowing it to compliantly address many of the most important jurisdictions in the global economy. Learn more at http://www.bridgetowercapital.com .
About Securitize
Securitize is a digital asset securities firm with a mission to provide stakeholders access to invest in and trade alternative investments, and for companies to raise capital, manage shareholders, and offer shareholders potential liquidity. Securitize has pioneered a fully digital, end-to-end platform for issuing, managing, and trading digital asset securities, consistent with the existing U.S. regulatory framework, with over 1.2 million investor accounts and 3,000 businesses connected. Securitize is comprised of Securitize, Inc. and its subsidiaries Securitize, LLC (an SEC-registered transfer agent), Securitize Capital, LLC, Securitize Markets, LLC (an SEC-registered broker-dealer, member of FINRA and SIPC , and operator of the company’s alternative trading system), and Pacific Stock Transfer. Learn more at http://www.securitize.io .
About Avalanche
Avalanche is the fastest smart contracts platform in the blockchain industry, as measured by time-to-finality. Avalanche is blazingly fast, low cost, and eco-friendly. Any smart contract-enabled application can outperform its competition by deploying on Avalanche. Don’t believe it? Try an app on Avalanche today.
Securitize Disclosures
Securities offered on the Securitize Markets ATS have not been registered under the Securities Act of 1933 and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. Assets listed herein, such as digital assets or tokens using blockchain, are speculative, involve a high degree of risk, are generally illiquid, may have no value, have limited regulatory certainty, are subject to potential market manipulation risks and may expose investors to loss of principal. Blockchain investing involves a degree of risk that can be different from traditional markets. These risks include, but are not limited to, risk of regulatory uncertainty, market adoption, market manipulation, market exiting, price volatility and security risk. Investments in private placements, start-up investments in particular, are also speculative and involve a high degree of risk. Investors must be able to afford the loss of their entire investment. Eligibility to buy and sell securities on the Securitize Markets ATS is determined by Securitize Markets in its sole discretion. Offers to sell, or the solicitations of offers to buy any security can only be made through official offering documents that contain important information about risks, fees and expenses associated with the applicable securities available for trading on the Securitize Markets ATS. Investors should conduct their own due diligence, and are encouraged to consult with a financial advisor, attorney, accountant, tax advisors, and any other professional that can help you to understand and assess the risks associated with any investment opportunity. Past performance is not indicative of future results. There is no guarantee that a diversified portfolio will enhance overall returns, outperform a non-diversified portfolio, or prevent against loss
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005733/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
